Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells

PADMAMALINI THULASIRAMAN and ANDREA BUTTS JOHNSON

Department of Biomedical Sciences, College of Allied Health, University of South Alabama, Mobile, AL 36688, USA

Received February 26, 2016; Accepted April 6, 2016

DOI: 10.3892/ijo.2016.3534

Abstract. Understanding the link between chemoresistance and cancer progression may identify future targeted therapy for breast cancer. One of the mechanisms by which chemoresistance is attained in cancer cells is mediated through the expression of multidrug resistance proteins (MRPs). Acquiring drug resistance has been correlated to the emergence of metastasis, accounting for the progression of the disease. One of the diagnostic markers of metastatic progression is the overexpression of a transmembrane protein called Mucin 1 (MUC1) which has been implicated in reduced survival rate. The objective of this study was to understand the relationship between MUC1 and MRPI using natural phenolic compound isolated from Magnolia grandiflora, honokiol, in mammary carcinoma cells. We provide evidence that honokiol suppresses the expression level of MUC1 and MRPI in mammary carcinoma cells. In a time-dependent manner, honokiol-mediated reduction of MUC1 is followed by a reduction of MRPI expression in the breast cancer cells. Additionally, silencing MUC1 suppresses the expression level of MRPI and enhances the efficacy of doxorubicin, an MRPI substrate. Taken together, these findings suggest MUC1 regulates the expression of MRPI and provides a direct link between cancer progression and chemoresistance in mammary carcinoma cells.

Introduction

Breast cancer is the most common type of cancer in women, with over one million cases diagnosed worldwide (1,2). Despite improvements in the development of chemotherapeutic drugs for breast cancer treatment, cancer related death rates continue to rise. Over time patients develop multidrug resistance (MDR) to chemotherapeutic drugs and this is a major factor in the failure of many forms of therapy, which can ultimately lead to tumor metastasis, affecting the quality of life of survivors and contributing to the mortality rate (3,4). Thus, it is of significant value to investigate the mechanism and pathways linked to drug resistance and metastasis in order to improve therapeutic treatments.

The development of resistance to chemotherapeutic agents occurs frequently in breast cancer patients and is a major factor for poor prognosis, mortality and morbidity in these patients (5). Among the strategies by which cancer cells acquire drug resistance is via the overexpression of ATP-binding cassette (ABC) transporters (6) which function as an energy-dependent efflux pump. The ABC transporters family include the P-glycoprotein (P-gp)/MDR belonging to the ABCB family (7). Included in the ABC superfamily are the multidrug resistance-protein (MRP) family of transporter proteins encoded by ABCC1-6, 10-13, the ATP-gated chloride channel, CFTR (ABCC7) and the ATP-dependent sulfonyleurea receptors, SUR (ABCC8, 9) (6). Of these, MRPI/ABCC1 is designated as a negative prognostic marker for early stage breast cancer, with reports linking a strong correlation of its expression to relapse and overall survival in several cancers (8-11). Although MRPI is expressed in normal tissues, several studies have demonstrated overexpression of MRPI in multiple solid tumors including breast, lung and prostate (6,12). Overexpression of MRPI in breast cancer lymph nodes has been associated to the metastatic potential of the disease (13). Expression pattern of MRPI makes this an optimal candidate for use as a marker for prediction of chemoresistance. Although the structure and function of ABC transporters have been explored in detail, developing effective agents against these transporters have not been translated into a clinical target (14).

Controlling cancer at the initial stage is vital in managing the disease. Tumor progression and metastasis within the body results in chemoresistance or an increase in chemotherapeutic dosage which ultimately causes cardiac toxicity (15). Hence, conventional therapeutic options have not been successful in halting the progression of the disease, and thus understanding the role of key proteins in the dissemination and metastasis of tumor cells will be essential in identifying effective and
innovative drug alternative to treat the disease at its initial or later stages. One of the diagnostic markers of metastatic progression is the overexpression of a transmembrane protein called Mucin 1 (MUC1) which has been implicated in reduced survival rate. Among the many functions associated with mucins, MUC1 is involved in cell growth, cell adhesion, motility and cell survival (16,17). MUC1 has also been implicated in chemoresistance and studies have shown that cancers overexpressing MUC1 are unresponsive to therapeutic chemotoxic drugs (18-20). A link between metastasis and chemoresistance has been observed in pancreatic cancer cells, whereby MUC1 has been shown to upregulate MRPI, lowering sensitivity to chemotherapeutic agents (18). This study from Nath et al (18) provides a mechanistic insight on the correlation between chemoresistance and metastasis in pancreatic cells. However, little is known on the relationship between MUC1 and MRPI in mammary carcinoma cells. Targeting both MRPI and MUC1 may provide an opportunity to intervene with drug resistance, and ultimately reduce the migration of cancer cells to other parts of the body, while augmenting the efficacy of chemotherapeutic drugs such as doxorubicin (DOX) against breast cancer cells.

Due to the cardiac toxicity associated with chemotherapeutic drugs such as DOX (15), various approaches to enhance chemoresistance in cancer models have been explored, including combining standard chemotherapy agents with natural products (21,22). Honokiol, isolated from the bark of the magnolia tree, has been found to have anti-oxidant (23), anti-inflammatory (24) and anticancer properties (25,26), promoting its potential for targeting various diseases, including cancer, arthritis, and diabetes (25-29). In addition to the multifaceted effects of honokiol, it has improved the actions of conventional chemotherapies to promote growth suppression or overcome drug resistance in a variety of preclinical models of human cancer, including skin cancer (30), prostate cancer (31) and multiple myeloma (32).

The study was aimed to investigate the relationship between the process of chemoresistance and cancer progression in mammary carcinoma cells by characterizing the effect of honokiol on MRPI and MUC1 gene expression, two proteins directly involved in these activities. In this study, we demonstrate that honokiol suppresses the expression of MUC1 and MRPI in mammary carcinoma cells. Based on these data, we provide mechanistic evidence that honokiol enhances the efficacy of DOX by regulating the expression of MUC1, which directly downregulates MRPI. Thus, understanding the mechanism by which honokiol promotes its anti-carcinogenic effects and prevents drug resistance may provide mechanistic insights into the underlying antitumor effects of honokiol, alone or in combination with chemotherapeutic agents, in breast cancer.

Materials and methods

Reagents. Antibodies against MUC1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and β-tubulin was purchased from Sigma Aldrich Co (St. Louis, MO, USA). Antibodies for MRPI were obtained from Abcam (Cambridge, MA, USA). Anti-mouse and anti-rabbit immunoglobulin horseradish peroxidase-conjugated antibodies were from Bio-Rad (Hercules, CA, USA), and anti-goat immunoglobulin was from Santa Cruz. Honokiol was obtained from LKT Laboratories (St. Paul, MN, USA) and DOX was purchased from Sigma. MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was purchased from Sigma. MUC1 and control siRNA were purchased from Santa Cruz Biotechnology.

Cell lines. MCF-7, MCF10A and MDA-MB-231 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) with antibiotics-antimycotics. DMEM was obtained from Life Technologies (Grand Island, NY, USA). FBS and antibiotics-antimycotics were purchased from Atlanta Biologicals (Flowery Branch, GA, USA). MCF-7 and MDA-MB-231 cells were a kind gift of Dr Ming Tan (Mitchell Cancer Institute, Mobile, AL, USA). MCF10A was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

Honokiol and DOX preparation. Honokiol was prepared at a stock concentration of 10 mM in dimethyl sulfoxide (DMSO) and cells were treated at the appropriate concentration, using DMSO as control. DOX was prepared at a stock concentration of 2 mM in water and diluted at the appropriate concentration for the treatment of cells.

Western blot analyses. Cells were cultured in 100-mm plates and treated with honokiol for either 24 or 48 h. DMSO was used as control. Cells were lysed in ice-cold buffer containing 150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA, and 1 mM PMSF. Cells were lysed on ice for 1 h and protein concentration was determined by the Bradford assay. Cell lysate was resolved by SDS-PAGE and blotted onto a nitrocellulose membrane. The membrane was blocked in 10% bovine serum albumin in Tris-buffer saline containing 0.05% tween for 1 h at room temperature. The membrane was then incubated with primary antibody, MUC1 or MRPI at a dilution of 1:1,000 overnight at 4°C. For equal loading, β-tubulin (1:1,000) was incubated with the membrane for 1 h at 4°C. The antigen-antibody complex was visualized with SuperSignal West Pico Chemiluminescent Substrate (Fisher, Hanover Park, IL, USA).

Quantitative real-time polymerase chain reaction (qRT-PCR). Cells were treated with honokiol for 48 h, and RNA was extracted using TRIzol (Life Technologies). As described in the high capacity RNA to cDNA kit from Applied Biosystems, 2 μg total RNA was reverse transcribed into cDNA. To determine expression of MUC1 and ABC1, qRT-PCR was carried out by using commercially available Taqman Chemistry and Assay on Demand Probes (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalization. Detection and data analysis were carried out on the ABI Step One Plus Real-Time PCR System. Relative quantity of gene expression was performed using 2−ΔΔCt method (33).

Cell viability assay. For cell proliferation assays, 5,000 cells of MDA-MB-231 and MCF-7 were seeded in a 96-well plate and allowed to adhere overnight. Cells were then treated with
honokiol in the presence or absence of DOX for 48 h. Controls were treated with or without DMSO depending on the drug treatment. After 48 h, 5 µg/ml MTT reagent was added directly to the cells for 3 h, or until crystals formed. The media was carefully removed from the plate, leaving the cells intact and the cells were then resuspended in 150 µl of 0.04 M HCl in isopropanol. Absorbance was read at 570 nm to determine cell proliferation.

Cell transfection. MCF-7 and MDA-MB-231 cells were transfected according to the protocol provided by Invitrogen (Grand Island, NY, USA). Briefly, 180 pmol of control or MUC1 siRNA was mixed with 2 ml Gibco Opti-MEM® I medium without serum by Life Technologies in a 100-mm plate. Lipofectamine™ RNAiMAX (25 µl) was added to the diluted RNAi mix and left for 20 min at room temperature. Cultured MCF-7 or MDA-MB-231 cells were subdivided and 2x10⁶ cells were diluted in the media. Cells were added to the plates containing the RNAi duplex/Lipofectamine™ mixture labeled with control or MUC1 siRNA. The cells were incubated for 48 h at 37°C in a CO₂ incubator. After 48 h, cells were lysed, protein was extracted, quantitated and protein extract was loaded onto a gel for SDS-PAGE. The blot was probed for MUC1 with MUC1 antibody to assay knockdown of the protein, and using the same extract, MRP1 protein expression was probed with MRP1 antibody.

Trypan blue exclusion assay. As described above, MCF-7 and MDA-MB-231 cells were transfected with control or MUC1 siRNA overnight, followed by treatment with 1 µM DOX for 48 h. After 48 h, cells were trypsinized, collected and counted using trypan blue. Live cells are presented as number of cells/ml.

Statistical analysis. Statistical significance of differences between treatments was determined using two tailed Student's t-test and p-values were noted. Differences between groups were considered statistically significant at p<0.05.

Results

Honokiol enhances the efficacy of DOX in mammary carcinoma cells. One of the advantages of honokiol is its lack of toxicity in non-tumorigenic cells, promoting its use with conventional chemotherapeutic agents (34). To compare the effects of honokiol on mammary carcinoma cells (MCF-7 and MDA-MB-231) with normal human mammary epithelial cells, we treated the cells with varying concentrations of honokiol. As observed previously (35,36), honokiol had moderate toxicity with a 50% decrease in cell proliferation at 25 and 28 µM honokiol in MCF-7 and MDA-MB-231 cells, respectively, while MCF10A were less sensitive to the anti-proliferative effects of honokiol (Fig. 1A).
Previous studies have shown that combining honokiol with chemotherapeutic agents in a variety of cancer cell lines increases the efficacy of chemotherapeutic agents by augmenting cell growth inhibition or inducing apoptosis (30-32,34,35). We evaluated the ability of honokiol to enhance the efficacy of DOX-mediated growth suppression in MCF-7 and MDA-MB-231. Given that 20 µM honokiol suppressed mammary carcinoma cell growth by ~33 and 20% in MCF-7 and MDA-MB-231 cells, respectively, we treated mammary carcinoma cells with 1 µM of DOX with a fixed 20 µM concentration of honokiol and analyzed cell proliferation using MTT assay. As shown in Fig. 1B and C, 1 µM DOX suppressed MCF-7 and MDA-MB-231 cell growth, respectively. As observed previously (Fig. 1A), honokiol at 20 µM reduced cell growth in MCF-7 and MDA-MB-231 cells (Fig. 1B and C). However, the combination of DOX with honokiol further increased the cell growth inhibitory properties of DOX and improved the potency of DOX in MCF-7 and MDA-MB-231 cells (Fig. 1B and C). This indicates that honokiol improves the efficacy of DOX, ultimately reducing the toxic effects of DOX.

**Honokiol regulates the expression of ABCC1/MRP1 in mammary carcinoma cells.** DOX is a substrate of MRP1 (37). To investigate whether the enhanced efficacy of DOX in mammary carcinoma cells (MCF-7 and MDA-MB-231) treated with honokiol was likely due to the associated changes of ABCC1 expression, we sought to assess the effect of honokiol on ABCC1 mRNA and protein expression in the non-metastatic MCF-7 cells and the highly aggressive MDA-MB-231 cells. To determine whether honokiol regulates the expression of ABCC1 in these mammary carcinoma cells, we treated MCF-7 and MDA-MB-231 mammary carcinoma cells with 10 and 20 µM honokiol for 48 h, and the levels of ABCC1 mRNA and protein were determined by qRT-PCR and western blotting, respectively. As shown in Fig. 2A, 10 and 20 µM honokiol equally suppressed ABCC1 mRNA levels in MCF-7 cells, without a dose response. Similarly, both 10 and 20 µM honokiol reduced ABCC1 mRNA expression in MDA-MB-231 cells by ~40 and 60%, respectively (Fig. 2B). The levels of the respective protein expression of ABCC1, MRP1 was also analyzed in these cells and consistent with ABCC1 mRNA expression in MCF-7 cells, 10 and 20 µM of honokiol reduced MRP1 protein expression in MCF-7 cells (Fig. 2C). To determine whether the inhibitory effects of honokiol on ABCC1 mRNA expression in MDA-MB-231 cells resulted in the suppression of MRP1 protein expression in MDA-MB-231 cells, western blotting was conducted. As shown in Fig. 2D, 20 µM honokiol suppressed MRP1 protein expression in MDA-MB-231 cells, while 10 µM honokiol had a moderate effect. These results indicate that honokiol suppresses ABCC1 mRNA and the expression of its respective protein, MRP1 in two different breast cancer cell lines, suggesting that the regulation of MRP1 by honokiol is a global effect among mammary carcinoma cells, emphasizing the importance of using honokiol to target drug resistance gene MRP1 in breast cancer.

**MUC1 is regulated by honokiol in mammary carcinoma cells.** Several studies have suggested the role of MUC1 in conferring drug resistance in cancer cells (18-20), while a study in pancreatic cancer cells specifically demonstrated regulation of MRP1 by MUC1 (18). In order to determine whether honokiol regulates MUC1 in mammary carcinoma cells, MCF-7 and MDA-MB-231 cells were treated with honokiol (10 and 20 µM) for 48 h and MUC1 mRNA expression level was analyzed. As shown in Fig. 3A and B, 10 and 20 µM honokiol suppressed MUC1 mRNA expression in both MCF-7 and MDA-MB-231
cells (Fig. 3A and B). Concomitantly, we examined the protein expression level of MUC1 in MCF-7 and MDA-MB-231 cells treated with honokiol and observed the downregulation of MUC1 protein in honokiol treated cells (Fig. 3C and D). These results demonstrate that honokiol suppresses MUC1 expression level in MCF-7 and MDA-MB-231 cells, suggesting the regulation of MUC1 by honokiol may be a global effect observed in breast cancer cells.

**Relationship between MUC1 and MRP1 protein expression in mammary carcinoma cells.** To further understand the relationship between MUC1 and MRP1 in mammary carcinoma cells, we specifically examined their protein expression level at 24 and 48 h of treatment with honokiol. Because significant downregulation of these proteins was observed with 20 µM honokiol, we treated MCF-7 and MDA-MB-231 cells with this concentration for 24 and 48 h, and analyzed the expression of these proteins at these two different time-points. Results from western blot analysis showed that 20 µM honokiol did not reduce either MUC1 or MRP1 expression at 24 h in either MCF-7 or MDA-MB-231 cells (Fig. 4). However, at 48 h, 20 µM honokiol reduced MUC1 expression and concomitantly MRP1 protein expression was downregulated in these cell lines (Fig. 4). These data suggest that there may be a correlation between the expression level of MUC1 and MRP1, and in fact reducing MUC1 suppresses MRP1 in mammary carcinoma cells.

**Suppression of MUC1 reduces the expression level of MRP1 and enhances the efficacy of DOX in mammary carcinoma cells.** To investigate whether regulation of MRP1 by honokiol is directly dependent on MUC1 pathway, we silenced MUC1 in mammary carcinoma cells (MCF-7 and MDA-MB-231) with MUC1 siRNA using Lipofectamine RNAimax. For control, we used a non-specific control siRNA. Equal amounts of cell lysates from control and MUC1 knockdown cells were lysed and probed for MUC1 protein expression. As shown in Fig. 5, MUC1 was silenced in both MCF-7 and MDA-MB-231 cells, respectively. Concomitantly, we examined the protein expression level of MRP1 in the control and MUC1 siRNA
transfected cells. Knock-down of MUC1 protein in MCF-7 cells suppressed MRP1 protein expression in these cells (Fig. 5A). Similarly, in MDA-MB-231 cells, MRP1 protein expression was suppressed in MUC1 silenced cells (Fig. 5B). With direct evidence to corroborate the findings from Fig. 4, these results suggest that MUC1 directly regulates MRP1 in mammary carcinoma cells.

Since MUC1 regulates MRP1, we next assessed the growth and inhibitory effects of DOX in mammary carcinoma cells transfected with control and MUC1 siRNA using trypan blue. MCF-7 and MDA-MB-231 cells were transfected with control or MUC1 siRNA, treated with 1 µM DOX for 48 h and cells were counted using trypan blue. The sensitivity to DOX in MUC1 siRNA transfected MCF-7 and MDA-MB-231 cells was significantly increased compared to the cells treated with the control siRNA (Fig. 5C and D). Taken together our results indicate that silencing MUC1 suppresses MRP1 which in turn enhances the efficacy of DOX-mediated growth suppression in mammary carcinoma cells.

Discussion

The role of MUC1 in promoting breast cancer development and its overexpression leading to mammary gland hyperplasia in mouse models is well established (38,39). MUC1 is well known to induce chemoresistance in several cancer types (18-20). To understand the relationship between MUC1 and MRP1 in breast cancer cells, we examined the effect of honokiol on these two proteins, while gaining insights on the functional consequence of regulating these genes. This study shows that honokiol downregulates the expression of MUC1 and MRP1 in breast cancer cell lines and increases the efficacy of DOX-mediated growth suppression. Silencing MUC1 gene expression in breast cancer cells reduces the expression of MRP1, and improves the potency of DOX to suppress cell growth. By examining the protein expression of MUC1 and MRP1 in honokiol-treated mammary carcinoma cells, we have observed that honokiol reduces MRP1 contingent upon the reduction of MUC1 expression. This report provides mechanistic data that regulation of MRP1 is dependent on MUC1 in mammary carcinoma cells, and combining honokiol with DOX reduces the toxic effects of this chemotherapeutic agent by modulating MUC1-mediated MRP1 expression.

Though MUC1 is well known for its metastatic properties, several mechanisms by which MUC1 confers chemoresistance have been reported and these mechanisms may be cancer type-specific or dependent on the chemotherapeutic agent. For instance, in breast, colon and thyroid cancer, MUC1 has been involved in blocking apoptosis induced by genotoxic or chemotherapeutic agents such as cisplatin by controlling the release of cytochrome c (20,40,41). In pancreatic cancer cells, previous study demonstrated that overexpression of MUC1 decreases sensitivity to chemotherapeutic drugs by increasing the expression of MRP1 (18). MUC1 immmunootherapy, including antibodies, vaccines or inhibitors against MUC1, has long been sought as a target of investigation, however, none of these therapies for MUC1 are under clinical applications (42). In this study, natural product honokiol, which is not toxic to normal breast epithelial cells, suppresses MRP1 and MUC1 expression at both the mRNA and protein level, suggesting a novel therapeutic inhibitor to block both chemoresistance and cancer

Figure 5. Knockdown of MUC1 reduces MRP1 expression and enhances the efficacy of doxorubicin. MCF-7 (A) and MDA-MB-231 (B) were transfected with control or MUC1 siRNA for 48 h, protein extracted and expression level of MUC1, MRP1 was examined by immunoblotting with antibodies recognizing MUC1 and MRP1, respectively. β-tubulin was used as loading control. MCF-7 (C) and MDA-MB-231 (D) were transfected with control or MUC1 siRNA, treated with 1 µM DOX for 48 h and live cells were counted using trypan blue. Data are mean of ± SE (n=3). *p=0.04 versus control; **p=0.01 versus control.
progression in breast cancer. However, it is beyond the scope of this study to determine how honokiol regulates MUC1 and future studies will be initiated to investigate this question.

Here, we provide evidence that honokiol-mediated down-regulation of MRPI is directed by suppression of MUC1. Thus, MUC1 regulates MRPI in mammary carcinoma cells. Though new chemosensitizers and novel ways such as RNA interference and epigenetic regulation are emerging as targets to overcome MDR, honokiol may provide an alternative means to regulate drug resistance and metastasis by suppressing the expression of the two proteins involved in this phenomenon, MRPI and MUC1, respectively. Although honokiol has been shown to suppress MDR gene product P-glycoprotein (43), this study focuses on the effect of honokiol on MRPI, which has been associated to shorter disease-free survival of breast cancer patients (8,13). A significant correlation between high expression levels of MRPI and response to treatment have been observed in breast tumors (8,13). Having observed that honokiol suppresses MRPI in triple-negative breast cancer cell line, MDA-MB-231 cells and estrogen receptor-positive mammary carcinoma cell line, MCF-7 promotes further investigation of using honokiol, in combination with traditionally used chemotherapeutic agents in breast cancer.

To extend these observations in breast cancer cells, we evaluated the relationship between MUC1 and MRPI in the mammary carcinoma cells MDA-MB-231 and MCF-7. We have shown that regulation of MRPI is directly dependent on MUC1 expression in the estrogen receptor-positive and triple-negative breast cancer cell lines. This suggested that down-regulation of MRPI by MUC1 would likely sensitize mammary carcinoma cells to chemotherapeutic agents. In light of the mounting evidence that there is a correlation between MUC1 and MRPI, we explored the relationship between MUC1 and MRPI in regulating resistance to chemotherapeutic agent, DOX, a substrate of MRPI. Accordingly, abrogation of MUC1 improved the responsiveness of mammary carcinoma cells to DOX. Interestingly, our data also showed that downregulation of MUC1 and MRPI by honokiol enhances the efficacy of DOX-mediated growth suppression. We provide mechanistic evidence that downregulation of MUC1 by honokiol suppresses MRPI which increases the potency of DOX.

Toxicity is an issue with chemotherapeutic drugs and limiting the dosage is a way to circumvent this problem. However, breast cancer patients may require higher dosages or may ultimately become resistant to chemotherapy. Along with existing drug treatments for breast cancer, the focus of clinicians and researchers have shifted towards exploring natural products. Various approaches to enhance chemoresistance in chemoresistant cancer models have been explored, including combining standard chemotherapy agents with natural products (44-46). Because of the toxicity associated with chemotherapeutic agents, combination with natural products that do not affect normal cells may improve the efficacy of chemotherapeutic drugs, while reducing the cardiac toxicity implicated with these agents. As shown in this study, the advantage of honokiol is that it does not affect normal breast cells and requires a high dose of honokiol (>50 μM) to even have a growth inhibitory effect in normal breast cancer cells. Combining DOX with honokiol improves the efficacy of DOX-mediated growth suppression in mammary carcinoma cells. By reducing the dosage of DOX by combinational treatment with honokiol, toxicity associated with chemotherapeutic agents such as DOX can be reduced.

Mechanistically, we provide evidence that honokiol improves the efficacy of DOX by modulating the interplay between MUC1 and MRPI. The interaction of multiple proteins in cancer progression poses a therapeutic challenge in controlling and managing the disease. Combinatorial treatment of chemotherapeutic regimen with agents that target different mechanisms of action in cancer progression, such as drug resistance and metastasis are warranted, especially in reducing the toxicity of standard chemotherapeutic agents. Future studies will further dissect the mechanism by which honokiol regulates MUC1 and its translational effect in cancer transformation. Nevertheless, this study demonstrates that honokiol enhances the efficacy of DOX by intervening in the crosstalk between MUC1 and MRPI in mammary carcinoma cells.

Acknowledgements

This study was supported by the start up funds from the College of Allied Health Professions at University of South Alabama. The authors would like to thank the Department of Pharmacology, University of South Alabama for use of their film developer.

References

1. Weigelt B, Peterse JL and van ’t Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer 5: 591-602, 2005.
2. Ripperger T, Gadzicki D, Meindl A and Schlegelberger B: Breast cancer susceptibility: Current knowledge and implications for genetic counselling. Eur J Hum Genet 17: 722-731, 2009.
3. McCubrey JA, Abrams SL, Fitzgerald TL, Cocco L, Martelli AM, Montalto G, Cervello M, Scalisi A, Candido S, Libra M, et al: Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Adv Biol Regul 57: 75-101, 2015.
4. Kerbel RS, Kobayashi H and Graham CH: Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? J Cell Biochem 56: 37-47, 1994.
5. Lønning PE: Molecular basis for therapy resistance. Mol Oncol 4: 284-300, 2010.
6. Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59: 752-757, 2007.
7. Deeley RG, Westlake C and Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006.
8. Nooter K, de la Riviere GB, Klijn J, Stoter G and Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885-1886, 1997.
9. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsurr A and Micksche M: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol 131: 355-363, 2005.
10. Bagnoli M, Beretta GL, Gatti L, Pilotti S, Alberti P, Tarantino E, Barbaresechi M, Canevari S, Mezzanzanca D and Perego P: Clinicopathological impact of ABCC1/MRP1 and ABCC4/ MRP4 in epithelial ovarian carcinoma. BioMed Res Int 2013: 143202, 2013.
11. Larbcharoensub N, Leopairat J, Sirachainan E, Narkwong L, Bhongmakapat T, Rasmeepaisarn K and Janvilisri T: Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39: 837-845, 2008.
12. Taheri M and Mahjoubi F: MRPI but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients. Dis Markers 34: 387-393, 2013.

13. Meibohm B, Schlegel R, Mertens M, Radas M, Brunner R, Kraujnic G, Suchomel R, Schmid K and Parker R: P-glycoprotein and MRPI expression in axillary lymph node metastases of breast cancer patients. Anticancer Res 21 (1A): 119-124, 2001.

14. Kathavala RJ, Gupta P, Ashby CR Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat 18: 1-17, 2015.

15. Chatterjee K, Zhang J, Honbo N and Karliner JS: Doxorubicin overcomes conventional drug resistance in human S.Elliptis myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106: 1794-1800, 2005.

16. Kufe DW: Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 9: 874-885, 2009.

17. Hollingsworth MA and Swanson BJ: Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 4: 45-60, 2004.

18. Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2: e51, 2013.

19. Deng M, Jing DD and Meng XJ: Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. Asian Pac J Cancer Prev 14: 127-131, 2013.

20. Ren J, Agata N, Di L, Yi Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175, 2004.

21. El-Sendony FF, Badria FA, El-Waseef AM, Chauhan SC and Halawesh F: Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumour Biol: Aug 5, 2015 (Epub ahead of print).

22. Yiannakopoulou EC: Interaction of green tea catechins with tumor metastasis and other bioactivities. Future Med Chem 5: 809-829, 2013.

23. Hu H, Zhang XX, Wang YY and Chen SZ: Honokiol inhibits stimulation of prostacyclin. Acta Pharmacol Sin 26: 1063-1068, 2005.

24. Kim BH and Cho JY: Anti-inflammatory effect of honokiol is mediated by PPARα/signal pathways and other bioactivities. Future Med Chem 5: 809-829, 2013.

25. Arora S, Singh AP: Honokiol: A novel natural agent for cancer prevention and cancer developments. Drug Discov Ther 7: 109-115, 2013.

26. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J and Kumar A, Kumar Singh U and Chaudhary A: Honokiol analogs: A novel class of anticancer agents targeting cell signaling pathways and other bioactivities. Anticancer Res 25 (4B): 2999-3005, 2005.

27. Raina D, Kharbanda S and Kufe D: The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xl pathways in rat 3Y1 fibroblasts. J Biol Chem 279: e86369, 2014.

28. Siragusa M, Zerilli M, Iovino F, Francipane MG, Lombardo Y, Sahraei M and Mukherjee P: MUC1 oncoprotein promotes refractoriness to chemotherapy in human prostate cancer cells. Oncogene 24: 3509-3516, 2015.

29. Chilampalli C, Zhang X, Kaushik RS, Young A, Zeman D, Hildreth MB, Fahmy H and Dwiwedi C: Chemopreventive effects of combination of honokiol and magnolol with γ-santalol on skin cancer developments. Drug Discov Ther 7: 109-115, 2013.

30. Shigemura K, Arbiser JL, Sun SY, Zayazafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhou HE and Chung LW: Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109: 1279-1289, 2007.

31. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraiishi N, Yasui H, Roccaro AM, Richardson P, et al: Honokiol overcomes conventional drug resistance in human S.Elliptis myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106: 1794-1800, 2005.

32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta Ct) method. Methods 25: 402-408, 2001.

33. Hu J, Chen LJ, Liu L, Chen X, Chen PL, Yang G, Hou WL, Tang MH, Zhang F, Wang XH, et al: Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic anti-tumor efficacy without increasing toxicity. Exp Mol Med 40: 617-628, 2008.

34. Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühl A, Schulz CO, Elstner E, Possinger K and Eucker J: Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol 591: 43-51, 2008.

35. Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, et al: Down-regulation of e-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 277: 133-140, 2009.

36. Hooijberg JH, Jansen K, Kathmann I, Pieters R, Laan AC, van Zantwijk I, Kaspers GJ and Peters GJ: Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 75: 911-917, 2014.

37. Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22: 6107-6110, 2003.

38. Schroeder JA, Masri AA, Adriane MC, Tessier JC, Kotlarczyk KL, Thompson MC and Gendler SJ: MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23: 5739-5747, 2004.

39. Halaweish F: Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumour Biol: Aug 5, 2015 (Epub ahead of print).

40. Raina D, Kharbanda S and Kufe D: The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xl pathways in rat 3Y1 fibroblasts. J Biol Chem 279: 20607-20612, 2004.

41. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL and Grandis JR: Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2571-2579, 2010.